Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca shares surge after key drug shows promise in lung cancer trial

05/12/2017 | 11:01am EDT
FILE PHOTO: The logo of AstraZeneca is seen on medication packages in a pharmacy in London

LONDON (Reuters) - A trial of AstraZeneca's (>> AstraZeneca plc) key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business.

LONDON (Reuters) - A trial of AstraZeneca's (>> AstraZeneca plc) key immunotherapy drug durvalumab showed it reduced disease progression in lung cancer patients, sending the company's shares higher and giving it a lead over rivals as it seeks to transform its oncology business.

The trial results are an unexpectedly early boost for the product, known commercially as Imfinzi, which the company hopes will become a blockbuster drug with sales in the billions of dollars.

It sets AstraZeneca apart from rivals Merck (>> Merck & Co., Inc.) and Roche (>> Roche Holding Ltd.), whose equivalent drugs are years behind in the race for similar treatments against lung cancer.

Shares in AstraZeneca extended gains to be up by 9.1 percent by mid-afternoon, the top FTSE 100 <.FTSE> riser, hitting its highest level since September 2016 and set for its biggest one day rise since May 2014.

Merck fell 1.5 percent, while Roche was up 0.9 percent.

AstraZeneca said it was in talks with the authorities over plans for regulatory approval.

"These are highly encouraging results for patients with locally-advanced lung cancer for whom surgery is not an option," Sean Bohen, Executive Vice President, Global Medicines Development at AstraZeneca, said in a statement.

Analysts said the results of the trial, known as PACIFIC, showed AstraZeneca was ahead of competitors as there was a gap in the market for such treatment. It also augured well for another trial due in mid-2017 which could mean the drug could be used in combination in newly diagnosed cases.

"The surprise early positive readout of the PACIFIC trial of... durvalumab (Imfinzi) in locally advanced lung cancer is a major inflection point for AstraZeneca's immuno-oncology," analysts at Deutsche Bank said in a note.

"In theory, this could open a market opportunity of $1.75 billion to $3.5 billion (or more) for the drug, which is not included in our current forecasts."


AstraZeneca is looking to sales of recently launched and experimental cancer medicines to help offset the impact of a loss of patents on blockbusters such as cholesterol pill Crestor.

The drug works by helping the body's immune cells kill cancer, offering an alternative to chemotherapy. In this trial it was used after chemotherapy or radiation therapy.

Analysts at Berenberg said that trial results, which were earlier than expected, put AstraZeneca ahead of rivals Roche and Merck. The results of their trials for similar treatments aren't expected until September 2019.

They also said the efficacy of durvalumab in PACIFIC was a good sign ahead of the results of a trial of the drug in a combination therapy, called MYSTIC. That is used on more advanced cancers, but before or instead of chemotherapy, and results are expected in June or July.

"While MYSTIC is still very important, PACIFIC clearly lessens its importance, and provides more reassurance that Imfinzi is an active drug and therefore must have a chance of working in MYSTIC," analysts at Berenberg said.

U.S. regulators earlier this month approved durvalumab as a treatment for bladder cancer, marking the first commercial green light for the product.

(Reporting by Alistair Smout,; additional reporting by Ben Hirschler in London and Caroline Humer in New York; Editing by Keith Weir)

By Alistair Smout

Stocks treated in this article : Merck & Co., Inc., AstraZeneca plc, Roche Holding Ltd.

ę Reuters 2017
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.68% 8236 Delayed Quote.12.68%
FTSE 100 -0.42% 6996.08 Delayed Quote.8.74%
MERCK & CO., INC. 0.79% 77.85 Delayed Quote.-5.57%
MSCI UNITED KINGDOM (STRD) 0.04% 1138.911 Real-time Quote.9.85%
NEXT PLC -0.89% 8040 Delayed Quote.13.46%
ROCHE HOLDING AG 0.00% 344.55 Delayed Quote.11.50%
S&P UNITED KINGDOM (PDS) -0.39% 1394.47 Delayed Quote.9.31%
SET -0.48% 1537.63 Real-time Quote.6.09%
THE LEAD CO., INC. -0.77% 648 End-of-day quote.-22.86%
All news about ASTRAZENECA PLC
10:18aTHE LATEST : Russia OKs test combo Sputnik, AstraZeneca shots
09:42aREGENERON PHARMACEUTICALS : AstraZeneca to Co-Develop, Commercialize New Small M..
08:54aASTRAZENECA : Russia OKs testing combination of Sputnik, AstraZeneca shots
07:10aASTRAZENECA : and Regeneron to research, develop and commercialise new small mol..
04:59aOmega Diagnostics Group Notes Use of Test in Study Tracking COVID-19 Antibody..
02:22aDassault Systemes lifts 2021 outlook on surging software sales
07/26FTSE 100 Delivers Weak Start to Week Despite Strong Mining Sector
07/26ASTRAZENECA : BYDUREON BCise (exenatide extended-release) approved in the US for..
07/26THE LATEST : France digests news of restaurant health passes
07/26ASTRAZENECA : BioNTech aims to develop mRNA-based malaria vaccine
More news
Financials (USD)
Sales 2021 35 226 M - -
Net income 2021 5 466 M - -
Net Debt 2021 17 526 M - -
P/E ratio 2021 28,3x
Yield 2021 2,46%
Capitalization 177 B 177 B -
EV / Sales 2021 5,54x
EV / Sales 2022 4,47x
Nbr of Employees 76 100
Free-Float 96,4%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | AZN | GB0009895292 | MarketScreener
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 114,56 $
Average target price 132,21 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC12.68%177 536
JOHNSON & JOHNSON9.21%452 602
ROCHE HOLDING AG11.50%327 852
PFIZER, INC.13.58%234 040
NOVARTIS AG-0.17%221 954